| |
 |
|
|
Bridgehead International Ltd strengthens
its capabilities in the neurosciences field.
October 2008
Bridgehead has announced that is has strengthened its capabilities in the neurosciences field through the appointment of Dr Martin Jones as an Associate. Dr Jones joins from GlaxoSmithKline, where he has been employed for over 19 years. His therapeutic expertise is in neurosciences, particularly migraine, having spent 11 years as clinical development leader of the post-marketing, life-cycle management of two highly successful acute migraine therapies (Imigran® and Naramig®). More recently he has been the clinical leader for a compound in early phase development for schizophrenia and in the past has worked on a variety of other disease areas: e.g. depression, Alzheimer's disease, pain, male erectile disorder.
Dr Jones will be working with Bridgehead clients to advise on candidate selection, development and delivery of global clinical trial programmes and the creation of high quality documents to support submissions, internal & external communications and governance. He will also participate in other Bridgehead assignments.
Bridgehead is a leading international, biopharmaceutical and medical technology consultancy group, offering a range of services designed to assist clients in achieving growth across the product and technology value chain. We specialise in strategy, transaction support (due diligence, valuation, partnering), product development support (market analysis, product positioning) and market access support (pricing, reimbursement). We work with many of the leading companies in these sectors, together with their financial advisors. We have over 50 consultants and associates in Europe, North America and Asia, providing a powerful combination of strategic, scientific, medical, technical, commercial, economic, decision support, financial modelling and intellectual property experience.
|
